1H-Pyrrole-2-carboxylic acid, 4-methyl-, 1H-benzotriazol-1-yl ester | 1374582-23-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 英文名称: 1H-Pyrrole-2-carboxylic acid, 4-methyl-, 1H-benzotriazol-1-yl ester
• 英文别名: benzotriazol-1-yl 4-methyl-1H-pyrrole-2-carboxylate
• CAS: 1374582-23-6
• 化学式: C₁₂H₁₀N₄O₂
• 分子量: 242.23
• InChiKey: TYSQMHDUYGDJEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• TRICYCLIC MGLUR5 RECEPTOR MODULATORS
  申请人：Anthony Neville J.

  公开号：US20130210804A1

  公开（公告）日：2013-08-15

  The present invention is directed to tricyclic compounds which are positive allosteric modulators of metabotropic glutamate receptors, particularly the mGluR5 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及三环化合物，它们是代谢型谷氨酸受体的正向变构调节剂，特别是mGluR5受体，并且它们在治疗或预防与谷氨酸功能障碍相关的神经系统和精神障碍以及代谢型谷氨酸受体参与的疾病中具有用途。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的疾病中的使用。
• [EN] TRICYCLIC MGLUR5 RECEPTOR MODULATORS<br/>[FR] MODULATEURS TRICYCLIQUES DES RÉCEPTEURS MGLUR5
  申请人：MERCK SHARP & DOHME

  公开号：WO2012061019A2

  公开（公告）日：2012-05-10

  The present invention is directed to tricyclic compounds which are positive allosteric modulators of metabotropic glutamate receptors, particularly the mGluR5 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.